Association studies of the copy-number variable ß-defensin cluster on 8p23.1 in adenocarcinoma and chronic pancreatitis
- Equal contributors
1 Genome Analysis, Leibniz Institute for Age Research - Fritz Lipmann Institute, Beutenbergstr 11, D-07745, Jena, Germany
2 Department of Visceral, Thoracic and Vascular Surgery, University Hospital, Technical University of Dresden, Dresden, Germany
3 Institute for Medical Epidemiology, Biostatistics and Informatics, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany
4 Institute for Medical Informatics and Statistics, Christian Albrechts University Kiel, Kiel, Germany
5 Institute for Clinical Molecular Biology, Christian Albrechts University Kiel, Kiel, Germany
6 German Cancer Research Centre, Division of Cancer Epidemiology, Heidelberg, Germany
7 Department of Medicine III, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany
8 Cologne Center for Genomics, University of Cologne, Cologne, Germany
Citation and License
BMC Research Notes 2012, 5:629 doi:10.1186/1756-0500-5-629Published: 13 November 2012
Human ß-defensins are a family of antimicrobial peptides located at the mucosal surface. Both sequence multi-site variations (MSV) and copy-number variants (CNV) of the defensin-encoding genes are associated with increased risk for various diseases, including cancer and inflammatory conditions such as psoriasis and acute pancreatitis. In a case–control study, we investigated the association between MSV in DEFB104 as well as defensin gene (DEF) cluster copy number (CN), and pancreatic ductal adenocarcinoma (PDAC) and chronic pancreatitis (CP).
Two groups of PDAC (N=70) and CP (N=60) patients were compared to matched healthy control groups CARLA1 (N=232) and CARLA2 (N=160), respectively. Four DEFB104 MSV were haplotyped by PCR, cloning and sequencing. DEF cluster CN was determined by multiplex ligation-dependent probe amplification.
Neither the PDAC nor the CP cohorts show significant differences in the DEFB104 haplotype distribution compared to the respective control groups CARLA1 and CARLA2, respectively.
The diploid DEF cluster CN exhibit a significantly different distribution between PDAC and CARLA1 (Fisher’s exact test P=0.027), but not between CP and CARLA2 (P=0.867).
Different DEF cluster b CN distribution between PDAC patients and healthy controls indicate a potential protective effect of higher CNs against the disease.